Research shows that positron emission tomography (PET) might allow clinicians to better monitor atezolizumab treatments in non-small cell lung cancer (NSCLC) patients. The findings came from a study that focused on immunotherapy but also supports the potential for PET as a way to assess various treatment effects and prognosis.
Non-small cell lung cancer is the most common form of lung cancer, making up 85% of cases. It is notoriously difficult to treat with chemotherapy, which makes various current immunotherapies more important than ever for giving patients a better chance to survive. Read more.